Whitney Ijem
Stock Analyst at Canaccord Genuity
(3.95)
# 555
Out of 4,955 analysts
107
Total ratings
53.26%
Success rate
10.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $52 → $66 | $53.50 | +23.36% | 5 | Aug 19, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 → $10 | $6.35 | +57.48% | 3 | Aug 18, 2025 | |
| PASG Passage Bio | Maintains: Buy | $260 → $67 | $7.60 | +781.58% | 7 | Aug 14, 2025 | |
| GUTS Fractyl Health | Maintains: Buy | $12 → $6 | $1.03 | +482.52% | 1 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $11 → $14 | $2.95 | +375.38% | 11 | Aug 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $136 → $128 | $29.74 | +330.40% | 9 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $424 → $411 | $397.21 | +3.47% | 9 | Aug 6, 2025 | |
| WVE Wave Life Sciences | Initiates: Buy | $19 | $10.38 | +83.04% | 1 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $390 → $415 | $459.13 | -9.61% | 9 | Aug 1, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 → $10 | $3.77 | +165.25% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $105 | $103.82 | +1.14% | 8 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $54 | $10.52 | +413.31% | 6 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $66 | $18.60 | +254.84% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $1.17 | +412.82% | 6 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $19.54 | +667.66% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $58.08 | +44.63% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $115.30 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $6.32 | +3,697.47% | 4 | Jul 23, 2019 |
Palvella Therapeutics
Aug 19, 2025
Maintains: Buy
Price Target: $52 → $66
Current: $53.50
Upside: +23.36%
Generation Bio Co.
Aug 18, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $6.35
Upside: +57.48%
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $260 → $67
Current: $7.60
Upside: +781.58%
Fractyl Health
Aug 14, 2025
Maintains: Buy
Price Target: $12 → $6
Current: $1.03
Upside: +482.52%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $2.95
Upside: +375.38%
Ultragenyx Pharmaceutical
Aug 8, 2025
Maintains: Buy
Price Target: $136 → $128
Current: $29.74
Upside: +330.40%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Hold
Price Target: $424 → $411
Current: $397.21
Upside: +3.47%
Wave Life Sciences
Aug 4, 2025
Initiates: Buy
Price Target: $19
Current: $10.38
Upside: +83.04%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $390 → $415
Current: $459.13
Upside: -9.61%
Rocket Pharmaceuticals
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.77
Upside: +165.25%
Jul 18, 2025
Maintains: Buy
Price Target: $92 → $105
Current: $103.82
Upside: +1.14%
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $10.52
Upside: +413.31%
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $18.60
Upside: +254.84%
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $1.17
Upside: +412.82%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $19.54
Upside: +667.66%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $58.08
Upside: +44.63%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $115.30
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $6.32
Upside: +3,697.47%